Literature DB >> 12510880

A validation study on the practical use of automated de novo design.

Martin Stahl1, Nikolay P Todorov, Tim James, Harald Mauser, Hans-Joachim Boehm, Philip M Dean.   

Abstract

The de novo design program Skelgen has been used to design inhibitor structures for four targets of pharmaceutical interest. The designed structures are compared to modeled binding modes of known inhibitors (i) visually and (ii) by means of a novel similarity measure considering the size and spatial proximity of the maximum common substructure of two small molecules. It is shown that the Skelgen algorithm generates representatives of many inhibitor classes within a very short time and that the new similarity measure is useful for comparing and clustering designed structures. The results demonstrate the necessity of properly defining search constraints in practical applications of de novo design.

Mesh:

Substances:

Year:  2002        PMID: 12510880     DOI: 10.1023/a:1021242018286

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  33 in total

1.  Rational discovery of novel nuclear hormone receptor antagonists.

Authors:  M Schapira; B M Raaka; H H Samuels; R Abagyan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  Scoring functions: a view from the bench.

Authors:  J R Tame
Journal:  J Comput Aided Mol Des       Date:  1999-03       Impact factor: 3.686

3.  Combinatorial computational method gives new picomolar ligands for a known enzyme.

Authors:  Bartosz A Grzybowski; Alexey V Ishchenko; Chu-Young Kim; George Topalov; Robert Chapman; David W Christianson; George M Whitesides; Eugene I Shakhnovich
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-29       Impact factor: 11.205

Review 4.  Structure-based virtual screening protocols.

Authors:  A Good
Journal:  Curr Opin Drug Discov Devel       Date:  2001-05

5.  Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.

Authors:  T A Grese; L D Pennington; J P Sluka; M D Adrian; H W Cole; T R Fuson; D E Magee; D L Phillips; E R Rowley; P K Shetler; L L Short; M Venugopalan; N N Yang; M Sato; A L Glasebrook; H U Bryant
Journal:  J Med Chem       Date:  1998-04-09       Impact factor: 7.446

6.  Evaluation of a method for controlling molecular scaffold diversity in de novo ligand design.

Authors:  N P Todorov; P M Dean
Journal:  J Comput Aided Mol Des       Date:  1997-03       Impact factor: 3.686

7.  Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists.

Authors:  S R Stauffer; C J Coletta; R Tedesco; G Nishiguchi; K Carlson; J Sun; B S Katzenellenbogen; J A Katzenellenbogen
Journal:  J Med Chem       Date:  2000-12-28       Impact factor: 7.446

8.  Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.

Authors:  M Barvian; D H Boschelli; J Cossrow; E Dobrusin; A Fattaey; A Fritsch; D Fry; P Harvey; P Keller; M Garrett; F La; W Leopold; D McNamara; M Quin; S Trumpp-Kallmeyer; P Toogood; Z Wu; E Zhang
Journal:  J Med Chem       Date:  2000-11-30       Impact factor: 7.446

9.  Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity.

Authors:  C Schultz; A Link; M Leost; D W Zaharevitz; R Gussio; E A Sausville; L Meijer; C Kunick
Journal:  J Med Chem       Date:  1999-07-29       Impact factor: 7.446

Review 10.  Structural approaches to explain the selectivity of COX-2 inhibitors: is there a common pharmacophore?

Authors:  G Dannhardt; S Laufer
Journal:  Curr Med Chem       Date:  2000-11       Impact factor: 4.530

View more
  9 in total

1.  The effect of a tightly bound water molecule on scaffold diversity in the computer-aided de novo ligand design of CDK2 inhibitors.

Authors:  Alfonso T García-Sosa; Ricardo L Mancera
Journal:  J Mol Model       Date:  2005-12-23       Impact factor: 1.810

Review 2.  Chemical genomics: a challenge for de novo drug design.

Authors:  P M Dean
Journal:  Mol Biotechnol       Date:  2007-06-30       Impact factor: 2.695

Review 3.  Computational methods in drug discovery.

Authors:  Gregory Sliwoski; Sandeepkumar Kothiwale; Jens Meiler; Edward W Lowe
Journal:  Pharmacol Rev       Date:  2013-12-31       Impact factor: 25.468

4.  De novo design by pharmacophore-based searches in fragment spaces.

Authors:  Tobias Lippert; Tanja Schulz-Gasch; Olivier Roche; Wolfgang Guba; Matthias Rarey
Journal:  J Comput Aided Mol Des       Date:  2011-09-16       Impact factor: 3.686

5.  Customizable de novo design strategies for DOCK: Application to HIVgp41 and other therapeutic targets.

Authors:  William J Allen; Brian C Fochtman; Trent E Balius; Robert C Rizzo
Journal:  J Comput Chem       Date:  2017-09-22       Impact factor: 3.376

6.  e-LEA3D: a computational-aided drug design web server.

Authors:  Dominique Douguet
Journal:  Nucleic Acids Res       Date:  2010-05-05       Impact factor: 16.971

7.  Automated design of ligands to polypharmacological profiles.

Authors:  Jérémy Besnard; Gian Filippo Ruda; Vincent Setola; Keren Abecassis; Ramona M Rodriguiz; Xi-Ping Huang; Suzanne Norval; Maria F Sassano; Antony I Shin; Lauren A Webster; Frederick R C Simeons; Laste Stojanovski; Annik Prat; Nabil G Seidah; Daniel B Constam; G Richard Bickerton; Kevin D Read; William C Wetsel; Ian H Gilbert; Bryan L Roth; Andrew L Hopkins
Journal:  Nature       Date:  2012-12-13       Impact factor: 49.962

8.  Molecular Design Method Using a Reversible Tree Representation of Chemical Compounds and Deep Reinforcement Learning.

Authors:  Ryuichiro Ishitani; Toshiki Kataoka; Kentaro Rikimaru
Journal:  J Chem Inf Model       Date:  2022-08-12       Impact factor: 6.162

9.  Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53-HDM2 Protein-Protein Interaction.

Authors:  Peter M Fischer
Journal:  Int J Pept Res Ther       Date:  2006-03-15       Impact factor: 1.931

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.